RXRX Today - Aug 06: Cash Burn Concerns

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

RXRX Today - Aug 06: Cash Burn Concerns

無料で聴く

ポッドキャストの詳細を見る

Hey there! I’m Joey, your friendly longtime investor, and I’m breaking down what went down with Recursion, or RXRX, today. Spoiler alert: it was a red day. The stock dipped about 0.36%.

So, here’s the scoop. RXRX got smoked today. It seems like cash burn is the big worry for folks right now. Investors are feeling the heat after the company reported a Q2 loss and missed revenue estimates. Not a great look, right? People were already on edge after the results update from August 5, and it seems like this just added fuel to the fire.

Now, let’s chat about why this happened. The articles are saying Recursion's been struggling with returns and is trading above what some think is fair value. Basically, it’s like when you’re trying to sell a used game for way too much, and no one’s biting. Plus, the whole AI drug development angle hasn’t been enough to convince everyone that it’s worth the price tag. Investors are questioning if the hype around AI in drug discovery is really living up to the expectations.

Oh, and here’s something worth knowing: Roche and Recursion are still pushing forward with their AI-targeted brain disease project. So, there’s some action happening in the lab, but it seems like the market’s not super jazzed about the immediate financials.

To wrap it up, RXRX is facing some tough questions from investors, and it’s clear that cash burn is a hot topic. Remember, I’m just here to share what’s happening, not to give any financial advice. Keep it chill, and see you next time!

まだレビューはありません